

Journal of Hepatology

CTAT methods

Tables for a “Complete, Transparent, Accurate and Timely account” (CTAT) are now mandatory for all revised submissions. The aim is to enhance the reproducibility of methods.

- Only include the parts relevant to your study
- Refer to the CTAT in the main text as ‘Supplementary CTAT Table’
- Do not add subheadings
- Add as many rows as needed to include all information
- Only include one item per row

If the CTAT form is not relevant to your study, please outline the reasons why:

/

1.1 Antibodies

Name	Citation	Supplier	Cat no.	Clone no.
Polyclonal rat anti-mouse F4/80	https://doi.org/10.1038/s41374-019-0315-9	AbD Serotec	MCA497G	A3-1
Polyclonal rat anti-mouse Ly6G	https://doi.org/10.1038/s41374-019-0315-9	BD Pharmingen	551459	1A8
Monoclonal rat anti-mouse CK19	https://doi.org/10.1016/j.jhep.2019.02.003	DSHB	Troma III	Not available
Polyclonal rabbit anti-rat	https://doi.org/10.1038/s41374-019-0315-9	Vector	AI-4001	Not available
Envision anti-rabbit-HRP	https://doi.org/10.1038/s41374-019-0315-9	Dako	K4003	Not available

1.2 Cell lines

Name	Citation	Supplier	Cat no.	Passage no.	Authentication test method
RAW264.7	https://www.atcc.org/products/tib-71	ATCC	TIB-71	4-5	Morphology check
L929	https://www.atcc.org/products/ccl-1	ATCC	CCL-1	8	Morphology check
HEK293T	https://www.atcc.org/products/crl-3216	ATCC	CRL-3216	17-20	Morphology check

1.3 Organisms

Name	Citation	Supplier	Strain	Sex	Age	Overall n number
C57BL/6J	https://www.jax.org/strain/000664	The Jackson Laboratory	C57BL/6J	M	28 weeks	20
<i>foz/foz</i> (<i>Alsm1</i> -/-)	https://doi.org/10.1210/me.2005-0494	GC Farrell	NOD.B10	M/F	18 weeks	40
WT mice (<i>Alsm1</i> +/+)	https://doi.org/10.1210/me.2005-0494	GC Farrell	NOD.B10	M/F	18 weeks	24

1.4 Sequence based reagents (primers)

Name	Forward sequence	Reverse sequence	Supplier
ASBT	TGGATAGATGGCGACATGGA	GGCAAGCAGTGTGGAGCAA	Invitrogen
BSEP	CTGCCAAGGATGCTAATGCA	CGATGGCTACCCTTTGCTTCT	Invitrogen
CYP27A1	GCCTCACCTATGGGATCTTCA	TCAAAGCCTGACGCAGATG	Invitrogen
CYP2A12	AAGGCTATGGTGTGGATTC	GTAGATGGTGGGGTCAATGG	Invitrogen
CYP2A22	GGGGACCGCTTCAACTACG	GTCCAGGGTACTGTGGTTGTG	Invitrogen
CYP7A1	AGCAACTAAACAACCTGCCAGTACTA	GTCCGGATATTCAAGGATGCA	Invitrogen
CYP7B1	TAGCCCTCTTTCCTCCAATCATA	GGCTGGCTTCCTGAGCTTATT	Invitrogen
CYP8B1	GGCTGGCTTCCTGAGCTTATT	ACTTCTGAACAGCTCATCGG	Invitrogen
FABP6	GTGGAAAGTAGACCGGAACGA	GGAAGCAGCAGAAGCTTGGT	Invitrogen
FGF15	GACCAAACGAACGAAATTTGTT	ACGTCTTGATGGCAATCG	Invitrogen
FXR	AGGAGCCCCTGCTTGATGT	GCGGGTTCTCAGGCTGGTA	Invitrogen
IL1 β	AGTTGACGGACCCCAAAAGA	GGACAGCCCAGGTCAAAGG	Invitrogen
MCP1	CCACTCACCTGCTGCTACTCAT	CTGCTGGTGATCCTCTTGT	Invitrogen
NTCP	CTTGCGCCATAGGGATCTTC	TGCCTGCCTTGAGGACGTA	Invitrogen
OST α	CCGTCAAGCCAAGATGCAT	CAAGCACCTGGAACAGAGCAA	Invitrogen
OST β	CCGGGGGAACCTGAGTAGAA	GTTATGGGGCGTTATGGGGT	Invitrogen
RPL19	GAAGGTCAAAGGGAATGTGTTCA	CCTTGCTGCCTTCAGCTTGT	Invitrogen
SHP	AGGGTAGAGGCCATGAGGAG	ACGATCCTCTTCAACCCAGA	Invitrogen
TGR5	GGCCTGGAACCTCTGTTATCG	GTCCCTCTGGCTCTTCCTC	Invitrogen
TNF α	GTGCCTATGTCTCAGCCTCTT	GCTCATACCAGGGTTTGAGCT	Invitrogen
VCAM1	AGTTGGGGATTTCGGTTGTTCT	CCCCTCATTCTTACCACCC	Invitrogen

1.5 Biological samples

Description	Source	Identifier
/	/	/

1.6 Deposited data

Name of repository	Identifier	Link
/	/	/

1.7 Software

Software name	Manufacturer	Version
Prism	GraphPad	9
Visiopharm	Visiopharm	
Rotor Gene Q	Qiagen	2.3.1
SoftMax Pro	Molecular Devices	7.1
CTAn	Blue Scientific	1.17.7.0

1.8 Other (e.g. drugs, proteins, vectors etc.)

High fat diet	ResearchDiets	D12492
Normal diet	SAFE Diets	A03
Western diet	ResearchDiets	D05011404
Fructose	Sigma	F0127
DCA	Sigma	D2510
TLCA	Sigma	T7515
LPS	Sigma	L2630
pCMV-SPORT6 human TGR5	Harvard Medical School	MGC:40597
pGL4.29	Promega	E8471
pGL4.73	Promega	E6911
Dual-Luciferase Reporter Assay System	Promega	E1910
Lipofectamine 2000 Transfection Reagent	Invitrogen	11668030
Diaminobenzidine	Dako	K3468
Mouse FGF15 ELISA kit	MyBioSource	MBS2019544
Ultrasensitive Mouse Insulin ELISA kit	Mercodia	10-1249-01
Total Bile Acid Assay	Diazyme	DZ042A

1.9 Please provide the details of the corresponding methods author for the manuscript:

Prof. Isabelle A. Leclercq;
 Laboratory of Hepato-Gastroenterology, Institute of Experimental and Clinical Research,
 Université catholique de Louvain, Brussels, Belgium;
 Avenue Mounier 53/B1.52.01, 1200 Woluwe-Saint-Lambert, Belgium;
 isabelle.leclercq@uclouvain.be

2.0 Please confirm for randomised controlled trials all versions of the clinical protocol are included in the submission. These will be published online as supplementary information.

Not applicable